CRTC1 and renal cell adenocarcinoma: Four of the seven objective responses reported in the expansion phase persisted for > 16 months: three patients with TORC1 inhibitor–naïve RCC (30 mg QW [n = 1], 40 mg QW [n = 2]) and one with TORC1 inhibitor failure RCC (5 mg QD).